OneRNA® for Next Generation Cures
Our OneRNA Platform for the developing next-generation cures
From early R&D through clinical strategy to executing and enrolling patients
Derisk and accelerate clinical studies
Using just one biomarker can save $1B
Using just one biomarker can dramatically derisk and accelerate drug approvals; however, relying on one biomarker alone can be risky and expensive to develop. OneRNA® doesn't cost anything upfront -
Expand label of existing drugs
Identify the indications your approved drugs could work in
Analyze which indications could potentially benefit from your already approved drugs and combine that information with an understanding of the unmet needs and competition. Identify which partner drugs could be tested in novel combinations expanding the patent life for your assets and develop novel partnering strategies
Design basket and umbrella studies
Mutation frquency in DNA is to low, whereas aberrant RNA is not
We have designed a combinatorial study with multiple immune therapy targets and checkpoint inhibitors. The design could “enroll” 30% of the target population based on the frequency of altered expression. This suggests that effective enrollment can be achieved using OneRNA®, whereas enrollment based on mutations alone can be difficult due to low penetration of a given mutation.
Attract patients to clinical studies
It can be challenging to attract patients with unique biomarkers
Most clinical studies have multiple biomarker inclusion criteria and there is only limited sample material available to test on. OneRNA® detects 20,000 mRNA at the same time with only 2 scrolls of tissue from an FFPE block. 80% of clinical studies fail due to lack of enrollment.
Companion diagnostic as an algorithm
Don't bet on the wrong biomarker
To develop and validate a companion diagnostic in parallel with a drug is like "landing an airplane on the top of a mountain". OneRNA® decreases the risk by turning the biomarker fishing expedition into a math equation, enabling the development of a responder algorithm (AI) that meets the study endpoint.
Design next-generation cures
Novel methods to rapidly translate RNA code to RNA Therapeutics
We are expanding the OneRNA® platform's translational capabilities and can envision a near future where we could manufacture truly individualized RNA Therapeutics from RNA Code to RNA Therapeutics in weeks.
